Immunopharmacologic properties of WY-16,922, a new orally effective antiallergic agent.
In a series of tests designed to illustrate immune reactions similar to those obtained in atopic disease, Wy-16,922 effectively inhibited reaginic-mediated immunologic reactions in the skin, longs and mast cell. It was found to be devoid of immunosuppressant, antimediator, anti-inflammatory, steroid or bronchodilator properties as well as acute toxicity. Although the mechanism of action Wy-16,922 is unknown, it appears to limit the release (not the effects) of allergic mediators in a manner similar to that described for disodium cromoglycate.
D000707:Anaphylaxis / Q000188:drug therapy; D000818:Animals; D002219:Carbamates / Q000494:pharmacology; D004205:Cromolyn Sodium / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects; D007109:Immunity / Q000187:drug effects*; D008168:Lung / Q000187:drug effects; D008297:Male; D008407:Mast Cells / Q000187:drug effects; D008614:Meperidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D010537:Peritoneum / Q000378:metabolism; D051381:Rats; D012867:Skin / Q000187:drug effects; D013997:Time Factors
D002219:Carbamates; D008614:Meperidine; D004205:Cromolyn Sodium